SNS-032CAS: 345627-80-7
MF: C17H24N4O2S2
MW: 380.53
A potent and selective Cdk inhibitor.

SNS-032 (CAS 345627-80-7)

SNS-032 | CAS 345627-80-7 is rated 5.0 out of 5 by 1.
  • y_2020, m_1, d_19, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364621, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 136ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Synonym: BMS-387032; N-(5-((5-tert-butyloxazol-2-yl)methylthio)thiazol-2-yl)piperidine-4-carboxamide
Application: A potent and selective Cdk inhibitor
CAS Number: 345627-80-7
Purity: ≥99%
Molecular Weight: 380.53
Molecular Formula: C17H24N4O2S2
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

SNS-032 (BMS-387032) is a potent and selective cyclin-dependent kinase inhibitor acting primarily on Cdk9 (IC50 = 4 nM), Cdk7 (IC50 = 63 nM), and Cdk2 (IC50 = 38 nM). SNS-032 (BMS-387032) is used in the treatment of B-cell malignancies and advanced solid tumors in vitro. SNS-032 (BMS-387032) was shown to inhibit in vitro angiogenesis and prostaglandin E2 (PGE2) production in vitro, both strongly associated with tumorigenesis. SNS-032 arrests the cell cycle at G2/M; inhibits transcription, proliferation and colony formation, and induces apoptosis in RPMI-8226 multiple myeloma cells invitro. Prevents tumor cell-induced VEGF secretion and in vitro angiogenesis.

Appearance :
Powder
Physical State :
Solid
Storage :
Store at -20° C
Melting Point :
165-167° C
Boiling Point :
548.11° C (Predicted)
Density :
1.29 g/cm3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
3025986
SMILES :
CC(C)(C)C1=CN=C(O1)CSC2=CN=C(S2)NC(=O)C3CCNCC3

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 121ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Han et al Han et al. (PubMed ID 26038136) found that the CDK inhibitor, SNS-032, can induce apoptosis of acute myeloid leukemia HL-60 cells via the inhibition of MCL-1,C-MYC and JAK2/STAT3, and down-regulation of miR-17-92 family. -SCBT Publication Review
Date published: 2015-04-12
  • y_2020, m_1, d_19, h_19
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.4
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_364621, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 21ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.